环磷酰胺用于干细胞动员可克服来那度胺治疗对多发性骨髓瘤干细胞采集的抑制作用。
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
作者信息
Mark Tomer, Stern Jessica, Furst Jessica R, Jayabalan David, Zafar Faiza, LaRow April, Pearse Roger N, Harpel John, Shore Tsiporah, Schuster Michael W, Leonard John P, Christos Paul J, Coleman Morton, Niesvizky Ruben
机构信息
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital-Cornell Medical Center, New York, New York 10021, USA.
出版信息
Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8. doi: 10.1016/j.bbmt.2008.04.008.
Abstract
A total of 28 treatment-naïve patients with stage II or III multiple myeloma (MM) were treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BiRD). Stem cells were collected following granulocyte-colony stimulating factor (G-CSF) or cyclophosphamide (Cy) plus G-CSF mobilization at maximum response. Sufficient stem cells for 2 autologous stem cell transplants were collected from all patients mobilized with Cy plus G-CSF, versus 33% mobilized with G-CSF alone (P < .0001). The duration of prior lenalidomide therapy did not correlate with success of stem cell harvests (P = .91). In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide.
摘要
共有28例初治的II期或III期多发性骨髓瘤（MM）患者接受了克拉霉素、来那度胺和地塞米松联合治疗（BiRD）。在最大反应时，采用粒细胞集落刺激因子（G-CSF）或环磷酰胺（Cy）加G-CSF动员后采集干细胞。所有接受Cy加G-CSF动员的患者均采集到足够进行2次自体干细胞移植的干细胞，而仅接受G-CSF动员的患者这一比例为33%（P < .0001）。来那度胺先前治疗的持续时间与干细胞采集的成功率无关（P = .91）。总之，Cy可添加到G-CSF中用于干细胞动员，以成功克服先前使用来那度胺治疗的抑制作用。
相似文献
1
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8. doi: 10.1016/j.bbmt.2008.04.008.
2
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
Bone Marrow Transplant. 2011 Jan;46(1):59-63. doi: 10.1038/bmt.2010.63. Epub 2010 May 3.
3
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Biol Blood Marrow Transplant. 2012 Jul;18(7):1128-35. doi: 10.1016/j.bbmt.2012.01.005. Epub 2012 Jan 14.
4
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
J Clin Apher. 2016 Oct;31(5):423-8. doi: 10.1002/jca.21421. Epub 2015 Sep 5.
5
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
J Clin Apher. 2015 Jun;30(3):176-82. doi: 10.1002/jca.21360. Epub 2014 Oct 8.
6
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
J Clin Apher. 2013 Oct;28(5):359-67. doi: 10.1002/jca.21280. Epub 2013 Jun 14.
7
Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.
Intern Med J. 2024 Jan;54(1):108-114. doi: 10.1111/imj.16170. Epub 2023 Jul 23.
8
Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Biol Blood Marrow Transplant. 2015 Jan;21(1):74-80. doi: 10.1016/j.bbmt.2014.09.020. Epub 2014 Sep 30.
9
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Biol Blood Marrow Transplant. 2009 Jun;15(6):718-23. doi: 10.1016/j.bbmt.2009.02.011. Epub 2009 Apr 8.
10
Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
Ann Hematol. 2017 Mar;96(3):461-467. doi: 10.1007/s00277-016-2897-2. Epub 2016 Dec 24.
引用本文的文献
1
Moving Beyond G-CSF Mobilization-Learning From a 15-Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma.
Cancer Med. 2025 Jul;14(14):e71068. doi: 10.1002/cam4.71068.
2
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma.
Ann Hematol. 2024 Oct;103(10):3839-3853. doi: 10.1007/s00277-024-05683-2. Epub 2024 Mar 6.
3
Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.
Ann Hematol. 2021 Feb;100(2):563-573. doi: 10.1007/s00277-020-04376-w. Epub 2021 Jan 6.
4
Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Int J Hematol. 2019 Jul;110(1):115-118. doi: 10.1007/s12185-019-02622-0. Epub 2019 Apr 13.
5
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.
Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9.
6
Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
Int J Hematol. 2018 May;107(5):559-567. doi: 10.1007/s12185-018-2408-4. Epub 2018 Jan 31.
7
Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
World J Transplant. 2017 Oct 24;7(5):250-259. doi: 10.5500/wjt.v7.i5.250.
8
Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean.
Bone Marrow Transplant. 2016 Mar;51(3):348-50. doi: 10.1038/bmt.2015.317. Epub 2015 Dec 21.
9
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435. doi: 10.6004/jnccn.2015.0167.
10
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
Bone Marrow Transplant. 2016 Mar;51(3):372-6. doi: 10.1038/bmt.2015.236. Epub 2015 Oct 5.
本文引用的文献
1
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
Leukemia. 2008 Jun;22(6):1282-4. doi: 10.1038/sj.leu.2405100. Epub 2008 Jan 24.
2
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Leukemia. 2008 Jun;22(6):1280-1; author reply 1281-2. doi: 10.1038/sj.leu.2405035. Epub 2007 Nov 22.
3
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596.
4
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594.
5
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Blood. 2008 Feb 1;111(3):1101-9. doi: 10.1182/blood-2007-05-090258. Epub 2007 Nov 7.
6
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
Mayo Clin Proc. 2007 Oct;82(10):1179-84. doi: 10.4065/82.10.1179.
7
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.
Blood. 2008 Feb 15;111(4):1805-10. doi: 10.1182/blood-2007-07-101212. Epub 2007 Sep 17.
8
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Br J Haematol. 2007 Sep;138(5):640-3. doi: 10.1111/j.1365-2141.2007.06698.x.
9
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Leukemia. 2007 Sep;21(9):2035-42. doi: 10.1038/sj.leu.2404801. Epub 2007 Jun 21.
10
Stem cell transplant for first relapse from the multiple myeloma research foundation.
Oncology (Williston Park). 2006 Dec;20(14):1818, 1820-1, 1825-6.
Zotero 插件